Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial - Sims, J R; Zimmer, J A; Evans, C D; TRAILBLAZER-ALZ 2 Investigators (JAMA, 2023)